Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Apr 21, 2021 10:57am
152 Views
Post# 33036834

RE:RE:RE:RE:RE:RE:Just a thought

RE:RE:RE:RE:RE:RE:Just a thoughtYou are right.
And if ATE holds tight, here's what likely happens (assuming a full buyout attempt) ...

1.  Big Pharma low balls the value of ATE in private discussions.
2.  ATE points to the research papers they paid for - showing annual sales potential.
Something we haven't heard much of ... ATE also argues the value of their patents and shows BP how new patents are on the way and ATB-340 (in parallel with a new molecule) will clearly demonstate how you get new IP to extend out 20 years for follow-on design and patent protection.
3.  There's a leak that BP is looking to buy ATE and the stock starts to climb.
3.  BP makes an offer and the share price rises.
4.  ATE indicates they are not interested in the offer as it doesn't represent the fair value for the business.
5.  ATE stock price continues to rise and settles where the market guesses the true value is.
6.  Other BP start pushing the pencil - to see if they can get in the game.
7.  The share price continues to rise on speculation.
8.  A second offer comes in ... and the real negotiations begin.

-----------------------

That's why we need Wallace/Legault to still have control over a large number of shares - and - we need lots of other shareholders to take their side in such a battle for the businesss.

We want the market to force the price on speculation ... if it doesn't want to cooperate and go there alone.

Something like that - just my opinion on one way it could happen.
<< Previous
Bullboard Posts
Next >>